| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| |
For the Three Months Ended
January 31,
|
| |
| |
2019
|
|
2018
|
|
Net loss:
|
|
|
|
|
|
|
Cchek™ cancer detection platform
|
$
|
(1,804,354)
|
|
$
|
(623,249)
|
|
CAR-T therapeutics
|
|
(2,487,285)
|
|
|
(1,109,018)
|
|
Patent licensing
|
|
(674,970)
|
|
|
(133,207)
|
|
Total
|
$
|
(4,966,609)
|
|
$
|
(1,865,474)
|
| |
|
|
|
|
|
|
Operating costs and expenses excluding non-cash
share based compensation:
|
|
|
|
|
|
|
Cchek™ cancer detection platform
|
$
|
759,534
|
|
$
|
525,614
|
|
CAR-T therapeutics
|
|
800,791
|
|
|
954,853
|
|
Patent licensing
|
|
673,239
|
|
|
127,146
|
|
Total
|
$
|
2,233,564
|
|
$
|
1,607,613
|
|
|
|
|
|
|
|
|
Operating costs and expenses excluding non-cash
share based compensation
|
$
|
2,233,564
|
|
$
|
1,607,613
|
|
Plus non-cash share-based compensation
|
|
2,750,164
|
|
|
266,973
|
|
Total operating costs and expenses
|
$
|
4,983,728
|
|
$
|
1,874,586
|
| |
January 31,
2019
|
|
October 31,
2018
|
| |
|
|
Total assets:
|
|
|
|
|
|
|
Cchek™ cancer detection platform
|
$
|
2,943,476
|
|
$
|
2,545,803
|
|
CAR-T therapeutics
|
|
3,112,658
|
|
|
2,157,359
|
|
Patent licensing
|
|
414,215
|
|
|
1,745,380
|
|
Total
|
$
|
6,470,349
|
|
$
|
6,448,542
|
|